Literature DB >> 16098822

Fluid retention mediated by renal PPARgamma.

Bart Staels1.   

Abstract

Thiazolidinediones are activators of the nuclear receptor PPARgamma with proven efficacy on glucose homeostasis. However, treatment with these drugs often results in fluid retention and edema. Recent studies establish a role for PPARgamma in renal sodium reabsorption, providing a mechanism for the plasma volume expansion induced by these drugs.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16098822     DOI： 10.1016/j.cmet.2005.08.001

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  16 in total

1.  Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

Authors:  Emily Borsting; Vicki Pei-Chun Cheng; Chris K Glass; Volker Vallon; Robyn Cunard
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-14

2.  Naturally improving insulin resistance with amorfrutins.

Authors:  Philippe Lefebvre; Bart Staels
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-27       Impact factor: 11.205

Review 3.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes.

Authors:  Stuart L Schreiber; Joanne D Kotz; Min Li; Jeffrey Aubé; Christopher P Austin; John C Reed; Hugh Rosen; E Lucile White; Larry A Sklar; Craig W Lindsley; Benjamin R Alexander; Joshua A Bittker; Paul A Clemons; Andrea de Souza; Michael A Foley; Michelle Palmer; Alykhan F Shamji; Mathias J Wawer; Owen McManus; Meng Wu; Beiyan Zou; Haibo Yu; Jennifer E Golden; Frank J Schoenen; Anton Simeonov; Ajit Jadhav; Michael R Jackson; Anthony B Pinkerton; Thomas D Y Chung; Patrick R Griffin; Benjamin F Cravatt; Peter S Hodder; William R Roush; Edward Roberts; Dong-Hoon Chung; Colleen B Jonsson; James W Noah; William E Severson; Subramaniam Ananthan; Bruce Edwards; Tudor I Oprea; P Jeffrey Conn; Corey R Hopkins; Michael R Wood; Shaun R Stauffer; Kyle A Emmitte
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

4.  Delivery of Polymeric Nanoparticles to Target Vascular Diseases.

Authors:  Edward Agyare; Karunyna Kandimalla
Journal:  J Biomol Res Ther       Date:  2014-01

5.  PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation.

Authors:  Ni-Huiping Son; Shuiqing Yu; Joseph Tuinei; Kotaro Arai; Hiroko Hamai; Shunichi Homma; Gerald I Shulman; E Dale Abel; Ira J Goldberg
Journal:  J Clin Invest       Date:  2010-09-13       Impact factor: 14.808

Review 6.  Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis.

Authors:  Daniel R Lewis; Kubra Kamisoglu; Adam W York; Prabhas V Moghe
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-04-26

7.  Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice.

Authors:  Ni-Huiping Son; Tae-Sik Park; Haruyo Yamashita; Masayoshi Yokoyama; Lesley A Huggins; Kazue Okajima; Shunichi Homma; Matthias J Szabolcs; Li-Shin Huang; Ira J Goldberg
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

8.  Systemic PPARγ deletion causes severe disturbance in fluid homeostasis in mice.

Authors:  Li Zhou; Alexandra Panasiuk; Maicy Downton; Daqiang Zhao; Baoxue Yang; Zhanjun Jia; Tianxin Yang
Journal:  Physiol Genomics       Date:  2015-09-01       Impact factor: 3.107

9.  Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.

Authors:  Daniela Bonofiglio; Erika Cione; Hongyan Qi; Attilio Pingitore; Mariarita Perri; Stefania Catalano; Donatella Vizza; Maria Luisa Panno; Giuseppe Genchi; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

10.  Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

Authors:  Volker Vallon; Edith Hummler; Timo Rieg; Oleh Pochynyuk; Vladislav Bugaj; Jana Schroth; Georges Dechenes; Bernard Rossier; Robyn Cunard; James Stockand
Journal:  J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.